[4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]Methanone
- Product Name
- [4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]Methanone
- CAS No.
- 924641-59-8
- Chemical Name
- [4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]Methanone
- Synonyms
- CS-1058;AZD 5597;pyrimidin-2-yl);(3-(methylamino);AZD 5597; AZD5597;-(4-((5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl);(S)-(4-((5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(3-(met;(S)-(4-((5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(3-(methyl;(S)-(4-((5-Fluoro-4-(1-isopropyl-2-Methyl-1H-iMidazol-5-yl)pyriMidin-2-yl)aMino)phenyl)(3-(MethylaMino)pyrrolidin-1-yl)Methanone;4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-ly]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]methanone
- CBNumber
- CB62473833
- Molecular Formula
- C23H28FN7O
- Formula Weight
- 437.51
- MOL File
- 924641-59-8.mol
[4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]Methanone Property
- Boiling point:
- 679.0±65.0 °C(Predicted)
- Density
- 1.32
- storage temp.
- 2-8°C(protect from light)
- solubility
- ≥1.82 mg/mL in H2O with ultrasonic; ≥12.7 mg/mL in EtOH; ≥15.65 mg/mL in DMSO
- form
- solid
- pka
- 9.66±0.20(Predicted)
N-Bromosuccinimide Price
- Product number
- 474066
- Product name
- AZD 5597
- Packaging
- 100mg
- Price
- $1848
- Updated
- 2021/12/16
- Product number
- CCH0033350
- Product name
- (S)-(4-((5-FLUORO-4-(1-ISOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL)AMINO)PHENYL)(3-(METHYLAMINO)PYRROLIDIN-1-YL)METHANONE
- Purity
- 95.00%
- Packaging
- 1G
- Price
- $1575
- Updated
- 2021/12/16
- Product number
- 094568
- Product name
- (S)-(4-((5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(3-(methylamino)pyrrolidin-1-yl)methanone
- Purity
- 95+%
- Packaging
- 1g
- Price
- $1647
- Updated
- 2021/12/16
- Product number
- 094568
- Product name
- (S)-(4-((5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(3-(methylamino)pyrrolidin-1-yl)methanone
- Purity
- 95+%
- Packaging
- 250mg
- Price
- $742
- Updated
- 2021/12/16
- Product number
- CCH0033350
- Product name
- (S)-(4-((5-FLUORO-4-(1-ISOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL)AMINO)PHENYL)(3-(METHYLAMINO)PYRROLIDIN-1-YL)METHANONE
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $1100
- Updated
- 2021/12/16
[4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]Methanone Chemical Properties,Usage,Production
Biological Activity
azd-5597 is a potent cdk inhibitor with ic50 values of 2 nm for cdk1 and cdk2, respectively [1].the cyclin-dependent kinases (cdks) are serine-threonine protein kinases with roles in the regulation of the cell cycle, and also involved in regulating transcription, mrna processing, and the differentiation of nerve cells [1].azd-5597 is a potent imidazole pyrimidine amide cdk inhibitor. in lovo cells, azd-5597 exhibited high level of anti-proliferative activity with ic50 value of 0.039 μm. azd-5597 exhibited excellent aqueous solubility ( > 50 mg/ml), photostability (t1/2 > 24 h), hydrolytic stability (ph 4-10, t1/2 > 100 days), plasma stability ( > 18 h) and the lack of cyp inhibition. the overall profile of azd-5597 indicated that it was suitable for further development as an iv agent [1].in nude mouse and rat, azd-5597 possessed good pharmacokinetic parameters with moderate to low clearance. in nude mice implanted subcutaneously with sw620 human colon adenocarcinoma cells, azd-5597 (15 mg/kg, dosed intermittently for 3 weeks, ip) inhibited tumour volume by 55% [1].
References
jones cd, andrews dm, barker aj, et al. the discovery of azd5597, a potent imidazole pyrimidine amide cdk inhibitor suitable for intravenous dosing. bioorganic & medicinal chemistry letters, 2008, 18(24): 6369-6373.